Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV trial of cetuximab plus radiotherapy vs 5-FU/mitomycin C plus radiotherapy in head and neck cancer
2013-001296-20Phase 4Terminated
- Sponsor
- Medical University of Innsbruck
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of cetuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Medical University of Innsbruck. Primary endpoint: Quality of life based on acute and late side effects. Started Dec 2013; status: terminated.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2013-001296-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001296-20.